Why in News?
Medical Technology Association of India (MTaI) has said that The National Pharmaceutical Pricing Authority (NPPA) should create sub-categories for stents to ensure consideration of technical superiority of each category of the stent while subjecting them to price capping.
FACTS FOR PRELIMS
Medical Technology Association of India (MTaI)
It is a not-for-profit organisation registered under Companies Act, 2013.
MTaI is an association of research-based medical technology companies who have made remarkable investments by setting up a large number of R&D centres and manufacturing plants in India. MTaI represents a wide spectrum of the medical device and equipment industry with global experience in innovation and manufacturing.
A stent is a tiny expandable metal scaffold inserted in the narrower or weakened arteries. The procedure of placing the stents in the arteries is called angioplasty.
In July 2016, stents were included in the National List of Essential Medicines (NLEM) and were added to the Schedule I of the Drug Prices Control Order, in December 2016, bringing the devices under price control. In February 2017, the NPPA had brought stents under price control and capped ceiling price of coronary stents. It was the first medical device to be brought under price control.
National Pharmaceutical Pricing Authority (NPPA)
i)NPPA is nodal government regulatory agency that controls the prices of pharmaceutical drugs in India. It functions under the aegis of Union Ministry of chemical and fertiliser
ii)NPPA decides the ceiling prices of essential medicines under The Drug (Prices Control) Order 2013.
iii)It advises Union Government on matters relating to drug policies and pricing and revisions/changes in the drug policy.